← All trials
NCT04581395
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 2, 2020
- Primary completion
- Sep 25, 2022
- Completion date
- Sep 25, 2022
- First posted
- Oct 9, 2020
- Last posted
- Nov 9, 2020
- Enrollment
- 300
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Indiana UniversityLead sponsor
- Indiana UniversityOverall official - principal investigator
- Indiana UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.